CAR.AU

39.48

+0.61%↑

WOR.AU

14.64

+0.55%↑

AZJ.AU

3.19

+0.31%↑

RSG.AU

0.69

0%↓

CAR.AU

39.48

+0.61%↑

WOR.AU

14.64

+0.55%↑

AZJ.AU

3.19

+0.31%↑

RSG.AU

0.69

0%↓

CAR.AU

39.48

+0.61%↑

WOR.AU

14.64

+0.55%↑

AZJ.AU

3.19

+0.31%↑

RSG.AU

0.69

0%↓

CAR.AU

39.48

+0.61%↑

WOR.AU

14.64

+0.55%↑

AZJ.AU

3.19

+0.31%↑

RSG.AU

0.69

0%↓

CAR.AU

39.48

+0.61%↑

WOR.AU

14.64

+0.55%↑

AZJ.AU

3.19

+0.31%↑

RSG.AU

0.69

0%↓

Search

CSL Ltd

Cerrado

SectorAcciones industriales

210.17 0.15

Resumen

Variación precio

24h

Actual

Mínimo

209.19

Máximo

210.4

Métricas clave

By Trading Economics

Ingresos

2B

Ventas

-5.7B

2.5B

P/B

Media del Sector

21.941

38.367

BPA

2.04

Rentabilidad por dividendo

1.39

Margen de beneficio

24.437

Empleados

29,904

EBITDA

-2.4B

858M

Recomendaciones

By TipRanks

Recomendaciones

Comprar

Estimación a 12 meses

+35.44% upside

Dividendos

By Dow Jones

Rentabilidad por dividendo

Media del Sector

1.39%

2.26%

Estadísticas de Mercado

By TradingEconomics

Capitalización de Mercado

-24B

100B

Apertura anterior

210.02

Cierre anterior

210.17

Noticias sobre sentimiento de mercado

By Acuity

38%

62%

142 / 459 Clasificación en Industrials

CSL Ltd Gráfico

El rendimiento pasado no es un indicador fiable de resultados futuros.

Noticias Relacionadas

19 ago 2025, 03:32 UTC

Principales Movimientos del Mercado

CSL Shares Slide 13% After Earnings, Seqirus Spin-Off Announcement

18 ago 2025, 23:46 UTC

Ganancias

CSL to Spin Off Seqirus, Cut Up to 15% of Staff in Sweeping Restructure -- Update

18 ago 2025, 22:15 UTC

Ganancias

CSL to Cut Up to 15% of Staff in $770 Million Restructure

9 abr 2025, 09:39 UTC

Principales Movimientos del Mercado

Pharma Stocks Tumble After Trump Threatens Tariffs on Medicines

10 feb 2025, 21:55 UTC

Ganancias

CSL Lifts 1st Half Net Profit by 3%, Led by Blood-Plasma Business -- Update

10 feb 2025, 21:34 UTC

Ganancias

CSL Lifts 1st Half Net Profit by 3%, Led by Blood-Plasma Business

18 ago 2025, 23:46 UTC

Charlas de Mercado
Ganancias

Investors May Have Lukewarm Reception to CSL's Earnings, Restructure -- Market Talk

18 ago 2025, 21:52 UTC

Ganancias

CSL to Record Up to $700M-$770M in FY26 Restructuring Costs>CSL.AU

18 ago 2025, 21:51 UTC

Ganancias

CSL to Cut Up to 15% of Staff>CSL.AU

18 ago 2025, 21:49 UTC

Ganancias

CSL Says It Closed 22 Underperforming U.S. Plasma Centers in August>CSL.AU

18 ago 2025, 21:49 UTC

Ganancias

CSL: Combination Will Deliver Synergies, Revenue Growth Opportunities>CSL.AU

18 ago 2025, 21:48 UTC

Ganancias

CSL to Combine Behring and Vifor Medical and Commercial Functions>CSL.AU

18 ago 2025, 21:47 UTC

Ganancias

CSL to Integrate R&D, Business Development, Commercial Teams>CSL.AU

18 ago 2025, 21:46 UTC

Ganancias

CSL: Transformational Initiatives to Reduce Costs, Simplfy Decision Making>CSL.AU

18 ago 2025, 21:45 UTC

Ganancias

CSL to Launch Multiyear Share Buyback in Fiscal 2026>CSL.AU

18 ago 2025, 21:45 UTC

Ganancias

CSL Intends Seqirus to Be Listed on the ASX>CSL.AU

18 ago 2025, 21:44 UTC

Ganancias

CSL Intends to Demerge Seqirus by End of FY 2026>CSL.AU

18 ago 2025, 21:43 UTC

Ganancias

CSL Raises Dividend to $1.62 Vs. $1.45 >CSL.AU

18 ago 2025, 21:43 UTC

Ganancias

CSL FY Underlying Net Profit $3.22B Vs. $2.91B>CSL.AU

18 ago 2025, 21:42 UTC

Ganancias

CSL FY Rev $15.56B Vs. $14.80B >CSL.AU

18 ago 2025, 21:42 UTC

Ganancias

CSL FY Net $3.00B Vs. Net $2.64B >CSL.AU

17 jun 2025, 02:15 UTC

Charlas de Mercado

Higher Margins Offered by CSL's Andembry Will Lift Earnings -- Market Talk

9 abr 2025, 07:01 UTC

Charlas de Mercado

CSL May Need to Raise Prices to Offset Trump's Potential Pharma Tariffs -- Market Talk

21 mar 2025, 02:03 UTC

Charlas de Mercado

Severe U.S. Influenza Season Could Benefit CSL -- Market Talk

11 feb 2025, 22:30 UTC

Charlas de Mercado

Flu Vaccines Proving Problematic for CSL -- Market Talk

10 feb 2025, 21:40 UTC

Ganancias

CSL Lifts 1H Net Profit by 3%, Led by Blood-Plasma Business -- Update

10 feb 2025, 21:19 UTC

Ganancias

CSL Lifts 1H Net Profit by 3%, Led by Blood-Plasma Business

10 feb 2025, 21:13 UTC

Ganancias

CSL Reaffirms Guidance for FY 2025 Net Profit of US$3.2 Billion-US$3.3 Billion at Constant FX

10 feb 2025, 21:12 UTC

Ganancias

CSL Interim Dividend US$1.30/Security

10 feb 2025, 21:12 UTC

Ganancias

CSL 1H Revenue US$8.48 Billion, Up 5% on Year

Comparación entre iguales

Cambio de precio

CSL Ltd Esperado

Precio Objetivo

By TipRanks

35.44% repunte

Estimación a 12 meses

Media 283.415 AUD  35.44%

Máximo 330 AUD

Mínimo 227.5 AUD

De acuerdo con 13 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para CSL Ltd Dist en los últimos 3 meses.

Consenso

By TipRanks

Comprar

13 ratings

9

Comprar

4

Mantener

0

Vender

Sentimiento

By Acuity

142 / 459 Clasificación en Acciones industriales

Noticias sobre sentimiento de mercado

Coyuntura alcista

Volatilidad

Por debajo de la media

Volumen de Noticias (RCV)

Por encima de la media

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

$

Acerca de CSL Ltd

CSL Limited researches, develops, manufactures, markets, and distributes biopharmaceutical and vaccines in Australia, the United States, Germany, the United Kingdom, Switzerland, China, Hong Kong, and internationally. The company operates through CSL Behring, CSL Seqirus, and CSL Vifor segments. The CSL Behring segment offers plasma products, gene therapies, and recombinants. The CSL Seqirus segment provides influenza related products and pandemic services to governments. The CSL Vifor segment offers products in the therapeutic areas of iron deficiency and nephrology. The company also licenses CSL intellectual property. CSL Limited was founded in 1916 and is headquartered in Melbourne, Australia.
help-icon Live chat